RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 95 filers reported holding RA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $8,750,000 | -27.3% | 182,245 | -28.9% | 0.00% | -33.3% |
| Q4 2019 | $12,035,000 | -88.2% | 256,439 | -94.1% | 0.00% | -87.0% |
| Q3 2019 | $102,048,000 | -34.5% | 4,314,947 | -16.7% | 0.02% | -32.4% |
| Q2 2019 | $155,767,000 | +35.2% | 5,180,168 | +0.7% | 0.03% | +30.8% |
| Q1 2019 | $115,223,000 | +20.4% | 5,143,899 | -2.2% | 0.03% | +8.3% |
| Q4 2018 | $95,695,000 | +83.7% | 5,257,952 | +82.6% | 0.02% | +118.2% |
| Q3 2018 | $52,089,000 | +82.0% | 2,879,432 | +0.1% | 0.01% | +83.3% |
| Q2 2018 | $28,613,000 | +85.3% | 2,875,637 | -1.1% | 0.01% | +100.0% |
| Q1 2018 | $15,440,000 | -34.4% | 2,907,497 | +5.1% | 0.00% | -40.0% |
| Q4 2017 | $23,521,000 | -29.7% | 2,767,243 | +20.7% | 0.01% | -37.5% |
| Q3 2017 | $33,478,000 | -15.1% | 2,293,041 | +8.9% | 0.01% | -11.1% |
| Q2 2017 | $39,449,000 | +13.6% | 2,105,064 | +29.0% | 0.01% | +12.5% |
| Q1 2017 | $34,733,000 | +45.2% | 1,631,429 | +3.6% | 0.01% | +33.3% |
| Q4 2016 | $23,923,000 | – | 1,574,979 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 3,851,808 | $20,453,000 | 1.57% |
| NEA Management Company, LLC | 5,493,636 | $29,171,000 | 1.30% |
| Foresite Capital Management IV, LLC | 450,000 | $2,390,000 | 0.99% |
| Novo Holdings A/S | 1,465,838 | $7,784,000 | 0.98% |
| Consonance Capital Management LP | 1,454,761 | $7,725,000 | 0.71% |
| VHCP Management II, LLC | 544,612 | $2,892,000 | 0.70% |
| ACUTA CAPITAL PARTNERS, LLC | 270,000 | $1,434,000 | 0.23% |
| Athanor Capital, LP | 67,150 | $357,000 | 0.16% |
| Rock Springs Capital Management LP | 600,000 | $3,186,000 | 0.14% |
| Eventide Asset Management | 388,000 | $2,060,000 | 0.10% |